bronchiolitis. acute bronchiolitis
Conditions
Interventions
Intervention 1: First group (A) received routine treatment of bronchiolitis and also received a drop phenyephrin 0.5% in supine position that remained in this position for 1 min. Intervention 2: The s
Treatment - Drugs
First group (A) received routine treatment of bronchiolitis and also received a drop phenyephrin 0.5% in supine position that remained in this position for 1 min.
The second group (B) received routine treatment of bronchiolitis and also recieved drop NaCl 0.9% in supine position that remained in this position for 1 min. Thirty minutes after administration of dr
Sponsors
Vice chancellory for Research, Zahedan University of Medical Sceiences
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: ages 4 weeks to 12 months; clinical diagnosis of viral bronchiolitis as the primary reason for hospitalization; presence of an oxygen requirement and a minimum severity score of 1. Exclusion criteria: history of chronic neurologic, heart, kidney, or lung disease; history of prematurity 10; use of nebulized albuterol or nebulized epinephrine within 4 hours of study enrollment; use of nasal phenylephrine or oxymetazoline within 12 hours of study enrollment; or “unstable” vital signs. “Unstable” vital signs are defined as heart rate >200 beats/min, blood pressure 2 standard deviations above or below the age appropriate mean, and respiratory rate above 80 breaths/min. The choice of maximum score is somewhat arbitrary but would exclude patients with all of the following: respiratory rate =70 breaths/min; intercostal, substernal and supraclavicular retractions; no feeding; and inspiratory and expiratory wheezing or diminished breath sounds.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory distress. Timepoint: 30 minutes after completion of therapy. Method of measurement: physical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulse rate. Timepoint: 30 minutes after completion of therapy. Method of measurement: physical examination.;O2 saturation. Timepoint: 30 minutes after completion of therapy. Method of measurement: physical examination.;Dyspenea. Timepoint: 30 minutes after completion of therapy. Method of measurement: physical examination.;Retraction. Timepoint: 30 minutes after completion of therapy. Method of measurement: physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarzieh Akbarpour
Zahedan University of Medical Sciences
Outcome results
None listed